Radiofrequency Ablation for Indeterminate Thyroid Nodules

This study is looking at how well Radiofrequency Ablation (RFA) works for treating certain thyroid nodules (lumps in your thyroid gland). RFA uses heat to treat the nodule. We are collecting information from patient records before and after they have the RFA procedure. You might be able to join if you are 18 or older, have an indeterminate Bethesda III thyroid nodule (a type of nodule that isn't clearly cancerous or non-cancerous), and your nodule has been confirmed as benign (not cancerous) by specific genetic tests (Afirma Genomic Sequencing Classifier or ThyroSeq v3). We are looking to see if RFA can change the size of the nodule after 12 months. The study status is currently unclear.

Study design
This is an observational study that will collect data from 50 participants. It is a chart review, meaning researchers will look at existing medical records.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at 12 months, suggesting participants will be followed for at least that long.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05189808

Radiofrequency Ablation for BIII Thyroid Nodules

Recruiting
Not specifiedAges 18+Observational
Columbia University
~50 participants
Updated 2026-05-29 on ClinicalTrials.gov
What's tested:Radiofrequency Ablation

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Nodule Volume
Measured over 12 months
Indeterminate Bethesda III Thyroid Nodules
1 sites across 1 states
New York1
  • Jennifer H Kuo, MD MS · PRINCIPAL_INVESTIGATOR · Columbia University

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Indeterminate Bethesda III nodules that have been molecularly profiled benign with either Afirma Genomic Sequencing Classifier (GSC) or ThyroSeq v3 tests

Exclusion

cardiac arrthymias
pregnancy
  • Change in Nodule Volume12 months

    ((Volume (baseline) - Volume (12m))/Volume(baseline))\*100